Last reviewed · How we verify
Azienda Ospedaliera di Perugia — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Aspirin plus clopidogrel | Aspirin plus clopidogrel | marketed | ||||
| Placebo, Palonosetron, Dexamethasone | Placebo, Palonosetron, Dexamethasone | phase 3 | 5-HT3 receptor antagonist + corticosteroid combination | 5-HT3 receptor (palonosetron); glucocorticoid receptor (dexamethasone) | Oncology (supportive care) |
Therapeutic area mix
- Oncology (supportive care) · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Government Medical College, Haldwani · 1 shared drug class
- Guangxi Medical University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliera di Perugia:
- Azienda Ospedaliera di Perugia pipeline updates — RSS
- Azienda Ospedaliera di Perugia pipeline updates — Atom
- Azienda Ospedaliera di Perugia pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliera di Perugia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-di-perugia. Accessed 2026-05-17.